CTLA4 and head and neck squamous cell carcinoma: In addition, based on the overexpression of CTLA-4 observed in HPV+ HNSCC tissue samples, a combination of anti-PD1 and anti–CTLA-4 therapies might be likely to achieve a better clinical outcome in HPV-related OSCC patients.